NCT05116085View on ClinicalTrials.gov

Efficacy and Safety of Tislelizumab (BGB-A317) as Neo-Adjuvant Treatment in Patients With Colorectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

January 26, 2022

Primary Completion Date

September 26, 2023

Study Completion Date

January 3, 2025

Conditions
Colorectal Cancer
Interventions
DRUG

Tislelizumab

Administered intravenously

Trial Locations (8)

110042

Liaoning Cancer Hospital and Institute, Shenyang

233004

The First Affiliated Hospital of Bengbu Medical College, Bengbu

250117

Shandong Cancer Hospital, Jinan

266000

The Affiliated Hospital of Qingdao University Branch South, Qingdao

300060

Tianjin Medical University Cancer Institute and Hospital, Tianjin

310009

The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou

430079

Hubei Cancer Hospital, Wuhan

510060

Sun Yat Sen University Cancer Center, Guangzhou

Sponsors

Lead Sponsor

BeiGene
All Listed Sponsors
lead

BeiGene

INDUSTRY

NCT05116085 - Efficacy and Safety of Tislelizumab (BGB-A317) as Neo-Adjuvant Treatment in Patients With Colorectal Cancer | Biotech Hunter | Biotech Hunter